Black Diamond Therapeutics, Inc. (BDTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Black Diamond Therapeutics, Inc. (BDTX) trades at $1.97 with AI Score 29/100 (Grade F). Black Diamond Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for genetically defined tumors. Market cap: $112.60M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for BDTX: BDTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BDTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BDTX: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Black Diamond Therapeutics, Inc. (BDTX) Healthcare & Pipeline Overview
Black Diamond Therapeutics is a biotechnology firm specializing in discovering and developing targeted medicines for patients with genetically defined tumors, particularly those with non-canonical EGFR and BRAF alterations. Their pipeline focuses on brain-penetrant inhibitors, positioning them in the precision oncology market.
What Is the Investment Thesis for BDTX?
Black Diamond Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing targeted therapies for genetically defined tumors, particularly those with EGFR and BRAF mutations, addresses a significant unmet medical need. Key value drivers include the clinical progress of BDTX-189, BDTX-1535, and BDTX-4933, with successful clinical trials and regulatory approvals representing major catalysts. The company's strategic partnership with OpenEye Scientific Software could accelerate drug discovery efforts. However, the company faces challenges typical of early-stage biotech companies, including clinical trial risks, regulatory hurdles, and the need for substantial capital to fund research and development. With a market cap of $112.60M and a beta of 3.39, BDTX exhibits significant volatility. The lack of a dividend reflects the company's focus on reinvesting earnings into its pipeline.
Based on FMP financials and quantitative analysis
BDTX Key Highlights
- Black Diamond Therapeutics focuses on precision oncology, developing targeted therapies for genetically defined tumors.
- The company's lead product candidate, BDTX-189, targets non-canonical EGFR and HER2 driver mutations.
- BDTX-1535 is a brain-penetrant inhibitor targeting EGFR mutations, including resistance mutations.
- BDTX-4933 is a brain-penetrant inhibitor of oncogenic BRAF class I, II, and III alterations.
- The company has a strategic partnership with OpenEye Scientific Software to enhance drug discovery.
Who Are BDTX's Competitors?
BDTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| ARRY Array Technologies, Inc. | $6.94 | -0.37% | $1.07B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $143.99 | -0.46% | 10B | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BDTX's Key Strengths?
- Focus on precision oncology and genetically defined tumors.
- Pipeline of brain-penetrant inhibitors.
- Strategic partnership with OpenEye Scientific Software.
- Experienced management team.
What Are BDTX's Weaknesses?
- Early-stage biotechnology company with limited revenue.
- High dependence on clinical trial outcomes.
- Requires significant capital to fund research and development.
- Limited commercialization experience.
What Could Drive BDTX Stock Higher?
- Clinical trial data releases for BDTX-189 in non-canonical EGFR and HER2 mutant cancers.
- Clinical trial data releases for BDTX-1535 in EGFR mutant cancers with brain metastases.
- Clinical trial data releases for BDTX-4933 in BRAF altered cancers with brain metastases.
- Potential for strategic partnerships or collaborations to accelerate drug development.
- Regulatory updates and potential approvals for lead product candidates.
What Are the Key Risks for BDTX?
- Financial-distress signal — its Altman Z-Score of -2.55 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-36.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and potential rejection of marketing applications.
- Competition from other biotechnology and pharmaceutical companies.
- Dependence on securing additional funding to support research and development.
- Patent challenges or loss of intellectual property protection.
What Are the Growth Opportunities for BDTX?
- Advancement of BDTX-189: BDTX-189, targeting non-canonical EGFR and HER2 mutations, represents a significant growth opportunity. The market for EGFR-targeted therapies is substantial, with a growing need for treatments that address resistance mechanisms. Successful clinical trials and regulatory approval could drive significant revenue growth for Black Diamond Therapeutics. The timeline for potential approval is dependent on clinical trial outcomes, with potential market entry within the next 3-5 years.
- Development of BDTX-1535: BDTX-1535, a brain-penetrant EGFR inhibitor, addresses a critical unmet need in patients with brain metastases. The brain cancer therapeutics market is expanding, driven by the increasing incidence of brain metastases and the limited availability of effective treatments. Positive clinical data and subsequent regulatory approval could establish BDTX-1535 as a valuable therapy. Expect potential market entry in 4-6 years.
- Progression of BDTX-4933: BDTX-4933, targeting oncogenic BRAF alterations, offers another growth avenue. BRAF mutations are prevalent in various cancers, and the development of a brain-penetrant inhibitor could provide a significant advantage. The BRAF inhibitor market is competitive, but a differentiated product profile could capture market share. Anticipate potential market entry in 5-7 years.
- Expansion of Pipeline: Black Diamond Therapeutics can leverage its expertise in precision oncology to expand its pipeline with additional targeted therapies. Identifying and developing novel inhibitors for other genetically defined tumors could diversify the company's product portfolio and reduce reliance on its current lead candidates. This would require ongoing investment in research and development, but could yield long-term growth opportunities. Expect new pipeline candidates within 2-3 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies or research institutions can accelerate drug development and commercialization efforts. Collaborations can provide access to additional resources, expertise, and funding, enhancing Black Diamond Therapeutics' ability to bring its therapies to market. These partnerships could also lead to the co-development of new therapies or the expansion of existing programs. Ongoing.
What Opportunities Does BDTX Have?
- Advancement of lead product candidates through clinical trials.
- Expansion of pipeline with additional targeted therapies.
- Strategic partnerships and collaborations.
- Growing market for precision oncology therapies.
What Threats Does BDTX Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology and pharmaceutical companies.
- Patent challenges.
What Are BDTX's Competitive Advantages?
- Proprietary drug discovery platform for identifying and developing targeted therapies.
- Focus on brain-penetrant inhibitors, addressing a critical unmet need in patients with brain metastases.
- Expertise in precision oncology, targeting specific genetic mutations driving tumor growth.
What Does BDTX Do?
Black Diamond Therapeutics, Inc. is a precision oncology company dedicated to creating innovative medicines for patients with genetically defined cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company emerged from ASET Therapeutics, Inc. in January 2018, marking a strategic shift towards its current focus. Black Diamond's core strategy revolves around developing small molecule inhibitors that target oncogenic proteins arising from non-canonical mutations. Their lead product candidate, BDTX-189, is designed to inhibit oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The company is also advancing BDTX-1535, a brain-penetrant inhibitor targeting EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations, and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. These programs reflect Black Diamond's commitment to addressing unmet needs in cancer therapy by developing therapies that can overcome resistance mechanisms and effectively target tumors in the brain. The company collaborates with OpenEye Scientific Software, Inc., leveraging advanced computational methods to accelerate drug discovery and development. Black Diamond's focus on precision oncology and brain-penetrant inhibitors positions them to potentially address significant challenges in cancer treatment.
What Products and Services Does BDTX Offer?
- Discovers and develops medicines for patients with genetically defined tumors.
- Develops BDTX-189, an irreversible small molecule inhibitor targeting non-canonical EGFR and HER2 mutations.
- Develops BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including resistance mutations.
- Develops BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.
- Focuses on precision oncology to target specific genetic mutations driving tumor growth.
- Utilizes a drug discovery platform to identify and develop novel inhibitors.
How Does BDTX Make Money?
- Develops and commercializes targeted therapies for genetically defined cancers.
- Generates revenue through the sale of approved therapies.
- Forms strategic partnerships and collaborations to accelerate drug development and commercialization.
What Industry Does BDTX Operate In?
Black Diamond Therapeutics operates within the competitive biotechnology industry, specifically targeting the precision oncology market. This market is characterized by rapid innovation, increasing demand for personalized therapies, and stringent regulatory requirements. The company competes with other biotechnology and pharmaceutical companies developing targeted cancer therapies. The industry is driven by advancements in genomics and molecular diagnostics, which enable the identification of specific genetic mutations driving tumor growth. The global precision medicine market is projected to reach billions of dollars in the coming years, reflecting the growing importance of targeted therapies in cancer treatment.
Who Are BDTX's Key Customers?
- Patients with genetically defined tumors, particularly those with EGFR and BRAF mutations.
- Oncologists and other healthcare professionals who treat cancer patients.
- Hospitals and cancer centers that provide cancer care.
Company Profile
Black Diamond Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Mark A. Velleca. BDTX has traded publicly since 2020.
How Black Diamond Therapeutics, Inc. Is Valued
Black Diamond Therapeutics, Inc. carries a market capitalization of $112.60M, placing it in the micro-cap category. Relative to its peer group, BDTX's quantitative score of 29/100 is below the peer average of 67/100.
ROE -36%Key Financial Metrics
Return on equity for Black Diamond Therapeutics, Inc. stands at -36.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Black Diamond Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.55 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Black Diamond Therapeutics, Inc. revenue of about $7.1M for fiscal 2026, with EPS near $-0.65. The estimate reflects 6 contributing analysts.
BDTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's long-term potential, indicating that key stakeholders believe in its future success.
- Community sentiment has shifted positively, with discussions highlighting optimism around ongoing clinical trials and their potential impact on the market.
- The company has made significant strides in its research pipeline, which has garnered attention and support from biotech enthusiasts and investors alike.
- Black Diamond's innovative approach to targeted therapies resonates with a growing trend towards precision medicine, attracting interest from both retail and institutional investors.
Bear Case
- Concerns have been raised regarding the pace of clinical trial results, leading to skepticism about the company's ability to deliver on its promises in a timely manner.
- Social sentiment has shown a mix of caution, with some community members expressing doubts about the sustainability of recent gains amidst regulatory uncertainties.
- Recent market developments have led to increased competition in the biotech space, putting pressure on Black Diamond to differentiate itself effectively.
- The overall volatility in the biotech sector has made some investors wary, leading to a more bearish outlook among those who prioritize stability over potential high rewards.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
BDTX Latest News
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · May 22, 2026
-
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jul 10, 2023
BDTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDTX.
Price Targets
Wall Street price target analysis for BDTX.
BDTX MoonshotScore
What does this score mean?
The MoonshotScore rates BDTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Black Diamond Therapeutics, Inc. Analysis
Leadership: Mark A. Velleca
CEO
Mark A. Velleca brings extensive experience in the biotechnology and pharmaceutical industries to his role as CEO of Black Diamond Therapeutics. His career spans various leadership positions in research and development, business development, and commercialization. He has a proven track record of driving innovation and building successful companies in the oncology space. Velleca's expertise encompasses drug discovery, clinical development, and strategic partnerships, making him well-suited to lead Black Diamond Therapeutics in its mission to develop targeted therapies for genetically defined tumors.
Track Record: Under Mark A. Velleca's leadership, Black Diamond Therapeutics has focused on advancing its pipeline of brain-penetrant inhibitors and expanding its research and development efforts. He has overseen the progression of BDTX-189, BDTX-1535, and BDTX-4933 through preclinical and clinical development stages. His strategic decisions have shaped the company's focus on precision oncology and its commitment to addressing unmet needs in cancer therapy.
BDTX Healthcare Stock FAQ
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for patients with genetically defined tumors. The company's pipeline includes small molecule inhibitors designed to address oncogenic mutations in EGFR and BRAF. Their lead product candidates, BDTX-189, BDTX-1535, and BDTX-4933, are designed to overcome resistance mechanisms and effectively target tumors, particularly in the brain. Black Diamond leverages its expertise in precision oncology to identify and develop novel inhibitors for specific genetic mutations driving tumor growth, aiming to provide personalized treatment options for cancer patients.
What do analysts say about BDTX stock?
Analyst coverage of Black Diamond Therapeutics reflects the inherent uncertainty and potential reward associated with early-stage biotechnology companies. Given the company's focus on novel cancer therapies, analysts closely monitor the clinical progress of BDTX-189, BDTX-1535, and BDTX-4933. Valuation metrics are heavily influenced by the perceived probability of success for these product candidates, with positive clinical data and regulatory milestones serving as key catalysts. Analyst opinions vary based on their assessment of these factors, but the consensus generally acknowledges the high-risk, high-reward nature of investing in BDTX. There is no consensus on buy or sell.
What are the main risks for BDTX?
Black Diamond Therapeutics faces several risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the company's lead product candidates may not demonstrate sufficient efficacy or safety in clinical studies. Regulatory hurdles pose another challenge, as the company must navigate complex approval processes and may face rejection of marketing applications. Competition from other biotechnology and pharmaceutical companies developing targeted cancer therapies also presents a risk. Furthermore, the company is dependent on securing additional funding to support its research and development efforts, and may face challenges in raising capital. Patent challenges or loss of intellectual property protection could also negatively impact the company's prospects.
What are the key factors to evaluate for BDTX?
Black Diamond Therapeutics, Inc. (BDTX) holds an AI score of 29/100 (low). P/E: 6.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does BDTX data refresh on this page?
BDTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BDTX's recent stock price performance?
Black Diamond Therapeutics, Inc. (BDTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on precision oncology and genetically defined tumors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BDTX overvalued or undervalued right now?
Black Diamond Therapeutics, Inc. (BDTX) trades at 6.6x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BDTX?
Before investing in Black Diamond Therapeutics, Inc. (BDTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Investment in biotechnology companies carries significant risk.